Myriad Genetics Inc (MYGN)

Currency in USD
3.87
-0.11(-2.76%)
Closed·
Pre Market
5.10+1.23(+31.78%)
·
MYGN Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual Pre-Market activity
Fair Value
Day's Range
3.854.05
52 wk Range
3.7629.30
Key Statistics
Prev. Close
3.87
Open
3.98
Day's Range
3.85-4.05
52 wk Range
3.76-29.3
Volume
2.89M
Average Volume (3m)
2.11M
1-Year Change
-85.02%
Book Value / Share
7.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MYGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.35
Upside
+89.82%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Myriad Genetics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Myriad Genetics Inc Company Profile

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Inc Earnings Call Summary for Q2/2025

  • Myriad Genetics reported Q2 2025 revenue of $213M, up 5% YoY, with adjusted EPS of $0.05, beating expectations
  • Company secured $200M term loan and raised FY2025 revenue guidance to $818-$828M, signaling confidence in growth prospects
  • Adjusted gross margins increased to 71.5%, up 140 basis points, reflecting operational efficiency improvements
  • CEO emphasized strategic focus on cancer care continuum and increased R&D investment in oncology for future growth
  • Stock rose 0.5% in aftermarket trading despite 2.76% drop during regular hours; company valued at $357.65M, deemed undervalued
Last Updated: 05/08/2025, 23:24
Read Full Transcript

Compare MYGN to Peers and Sector

Metrics to compare
MYGN
Peers
Sector
Relationship
P/E Ratio
−3.5x−4.6x−0.5x
PEG Ratio
−0.06−0.190.00
Price/Book
0.5x3.0x2.6x
Price / LTM Sales
0.4x7.9x3.3x
Upside (Analyst Target)
55.0%289.1%42.8%
Fair Value Upside
Unlock−7.8%6.5%Unlock

Analyst Ratings

3 Buy
9 Hold
3 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 7.35
(+89.82% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.05 / -0.01
Revenue / Forecast
213.10M / 201.91M
EPS Revisions
Last 90 days

MYGN Income Statement

People Also Watch

16.75
SRPT
-2.05%
6.32
REPL
+10.68%
6.945
TRON
-5.70%
25.01
VCYT
+2.84%
137.35
KRYS
+1.79%

FAQ

What Stock Exchange Does Myriad Genetics Trade On?

Myriad Genetics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Myriad Genetics?

The stock symbol for Myriad Genetics is "MYGN."

What Is the Myriad Genetics Market Cap?

As of today, Myriad Genetics market cap is 356.73M.

What Is Myriad Genetics's Earnings Per Share (TTM)?

The Myriad Genetics EPS (TTM) is -1.11.

When Is the Next Myriad Genetics Earnings Date?

Myriad Genetics will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is MYGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Myriad Genetics Stock Split?

Myriad Genetics has split 2 times.

How Many Employees Does Myriad Genetics Have?

Myriad Genetics has 2700 employees.

What is the current trading status of Myriad Genetics (MYGN)?

As of 06 Aug 2025, Myriad Genetics (MYGN) is trading at a price of 3.87, with a previous close of 3.87. The stock has fluctuated within a day range of 3.85 to 4.05, while its 52-week range spans from 3.76 to 29.30.

What Is Myriad Genetics (MYGN) Price Target According to Analysts?

The average 12-month price target for Myriad Genetics is USD7.34615, with a high estimate of USD18 and a low estimate of USD3.5. 3 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +89.82% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.